Primary Immunodeficiency

Utilization data from the Central Transfusion Registry shows that IG use in BC has been increasing at approximately 10% per year.

Immunology comprises the largest speciality and accounts for 45% of Provincial IG use. The condition Primary Immunodeficiency or Primary Immune Deficiency Disease (PIDD) accounts for approximately 60% of IG used for immunology patients and the growth of utilization year over year has been significant. Highlights of our analysis demonstrate increasing annual dosage, prescriber variation and a steady increase in new and chronic patients, particularly in the sixth and seventh decade of life.

In 2016 the PIDD Working Group was formed in order to help establish a provincial framework for IG use in PIDD. The Working Group representatives include: Dr. Doug Morrison (co-chair), Dr. Karen Dallas (co-chair), Dr. Bob Schellenberg, Dr. Donald Stark, Dr. Hein Reeves, Dr. Peter Lee, Dr. Kingsley Lee , Dr. Seung Kim, and Dr. Kyla Hildebrand.

The Working Group participated in the development of the Diagnostic and Treatment Algorithms as well as the PIDD Toolkit App.

References
Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe (Front. Immunol., 12 December 2014)
Use and Clinical Interpretation of Pneumococcal Antibody Measurements in the Evaluations of Humoral Immune Function (Clin Vaccine Immunol February 2015)  
Practical Guide for Allergy and Immunology in Canada: Primary Immunodeficiency (Allergy, Asthma & Clinical Immunology 10 November 2011)  
Immunoglobulins and Obesity (Pharmacy Practice News, January 2010)  
Additional Information  
Information Regarding Dose Calculator
Canadian Society of Allergy and Clinical Immunology
American Academy of Allergy Asthma & Immunology 

 

If you have questions or would like to learn more, please contact PBCO